Sauter C, Fehr J, Frick P, Gmuer J, Honegger H, Martz G
Eur J Cancer Clin Oncol. 1982 Aug;18(8):733-7. doi: 10.1016/0277-5379(82)90071-2.
Between March 1980 and January 1982, 15 patients with acute myelogenous leukemia (AML) in relapse were treated with one or more cycles of a combination chemotherapy consisting of cytosine arabinoside (Ara-C), VP 16-213, vincristine and vinblastine (A-triple-V). Of a total of 20 treatment cycles given, one partial and 15 complete remissions were achieved, there was no change in the bone marrow in two cases, one patient died due to Pseudomonas septicemia during an apparently normal bone marrow regeneration and one patient died of Candida infection while in aplasia. With 15 out of 20 (75%) successful relapse treatment courses, A-triple-V should be tested in first-line protocols.
1980年3月至1982年1月期间，15例急性髓性白血病（AML）复发患者接受了一个或多个周期的联合化疗，该联合化疗由阿糖胞苷（Ara-C）、依托泊苷（VP 16-213）、长春新碱和长春花碱组成（A-三联-V）。在总共进行的20个治疗周期中，1例部分缓解，15例完全缓解，2例骨髓无变化，1例患者在骨髓明显正常再生期间死于铜绿假单胞菌败血症，1例患者在再生障碍性贫血时死于念珠菌感染。20个复发治疗疗程中有15个（75%）成功，应在一线方案中对A-三联-V进行试验。
